Report: Current Stock Reports

Conclusion of an agreement concerning operational execution of Phase I clinical trial of RVU120 (SEL120) in solid tumors
March 8, 2021

Ryvu Therapeutics project regarding Phase I/II clinical study of SEL120 (RVU 120) in solid tumors recommended for financing by NCBiR
January 18, 2021

Publication dates for periodic reports in 2021
January 13, 2021

Ryvu Therapeutics to expand its Phase I study of SEL120 (RVU120) in patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome to Poland
January 7, 2021

The new Clinical Trial Application for the conduct of a Phase I/II study of RVU120 (SEL120) in patients with solid tumors submitted by Ryvu Therapeutics S.A.
January 4, 2021

Three Posters on SEL24/MEN1703 including Pharmacodynamic Data from the Dose Escalation Part of DIAMOND-01 Trial to be published at American Society of Hematology (ASH) Annual Meeting
December 1, 2020

Appointment of the new Management Board Member of Ryvu Therapeutics S.A.
November 23, 2020

Revision of the Company’s research project pipeline
October 21, 2020

Ryvu Therapeutics abstract concerning the STING program accepted for presentation at the SITC 2020
October 14, 2020

Change of the registered office address of Ryvu Therapeutics S.A.
October 12, 2020

First patient dosed in Europe within the Expansion Cohort of Phase I/II Clinical Study of SEL24/MEN1703
September 16, 2020

Appointment of Members of the Company’s Management and Supervisory Boards for a new term of office
September 1, 2020

Shareholders controlling at least 5% of the vote at the General Meeting of Ryvu Therapeutics S.A. held on August 31, 2020
August 31, 2020

Resolutions adopted by the Annual General Shareholders Meeting of Ryvu Therapeutics S.A.
August 31, 2020

Introduction of the Series I Shares to trading on the main market operated by the WSE and designation of the last day of listing of Rights to Series I Shares
August 26, 2020

Registration of share capital increase
August 19, 2020

Completion of the subscription of Series I Shares
August 5, 2020

Introduction of the Rights to Series I Shares to trading on the main market operated by the WSE
July 30, 2020

Registration of the Rights to Series I Shares in the book-entry form by the National Depository for Securities
July 27, 2020

Execution of subscription agreements and collection of cash contributions relating to series I shares in Ryvu Therapeutics S.A.
July 22, 2020